# Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

> **NCT04065087** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Genexine, Inc.**

## Conditions studied

- Newly Diagnosed Glioblastoma

## Interventions

- **BIOLOGICAL:** GX-I7
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04065087
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-08-22
- **Primary completion:** 2022-05-27
- **Final completion:** 2022-08-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Canceled by the sponsor
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04065087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04065087, "Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04065087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*